| Member | Buys | Sells | Est. net | Last move |
|---|---|---|---|---|
| Josh Gottheimer NJ05 | 1 | −$8.0K | Sold Nov 19, 25 | |
| Jefferson Shreve IN06 | 1 | 1 | −$42.5K | Sold May 12, 25 |
| Bruce Westerman AR04 | 1 | 1 | +$0 | Sold Apr 21, 25 |
| Rob Bresnahan PA08 | 1 | +$8.0K | Bought Apr 8, 25 |
| Traded | Member | Owner | Type | Amount | Filed | Report |
|---|---|---|---|---|---|---|
| Nov 19, 25 | Josh Gottheimer NJ05 | Joint | Sell | $1,001 - $15,000 | Dec 29, 25 (40d) | |
| May 12, 25 | Jefferson Shreve IN06 | Self | Sell | $50,001 - $100,000 | Jun 22, 25 (41d) | |
| Apr 21, 25 | Bruce Westerman AR04 | Self | Sell | $1,001 - $15,000 | May 12, 25 (21d) | |
| Apr 8, 25 | Rob Bresnahan PA08 | Self | Buy | $1,001 - $15,000 | May 8, 25 (30d) | |
| Apr 7, 25 | Jefferson Shreve IN06 | Self | Buy | $15,001 - $50,000 | May 8, 25 (31d) | |
| Mar 3, 25 | Bruce Westerman AR04 | Self | Buy | $1,001 - $15,000 | Apr 16, 25 (44d) |
From the House's STOCK Act reports (Senate not included). Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 7, 2026 | Lippis Daniel JOfficer | Sale at price 85.65 per share. | 619 | $53.02K |
| Oct 7, 2026 | Lippis Daniel JOfficer | Conversion of Exercise of derivative security at price 72.68 per share. | 619 | $44.99K |
| Sep 10, 2026 | Lippis Daniel JOfficer | Sale at price 87.51 per share. | 619 | $54.17K |
| Sep 10, 2026 | Lippis Daniel JOfficer | Conversion of Exercise of derivative security at price 72.68 per share. | 619 | $44.99K |
| Aug 30, 2026 | Dahl Andrew MOfficer | Sale at price 91.06 per share. | 544 | $49.53K |
| Aug 27, 2026 | Bruls AnnetteOfficer | Sale at price 89.98 per share. | 2.6K | $237.91K |
| Aug 25, 2026 | Chopra DaveenOfficer | Sale at price 90.99 - 91.76 per share. | 31.8K | $2.89M |
| Aug 25, 2026 | Markowitz WayneOfficer | Sale at price 91.46 per share. | 1.2K | $113.42K |
| Aug 25, 2026 | Chopra DaveenOfficer | Conversion of Exercise of derivative security at price 72.68 per share. | 31.8K | $2.31M |
| Aug 10, 2026 | Lippis Daniel JOfficer | Sale at price 92.03 per share. | 619 | $56.97K |
| Aug 10, 2026 | Lippis Daniel JOfficer | Conversion of Exercise of derivative security at price 72.68 per share. | 619 | $44.99K |
| Jul 29, 2026 | Markowitz WayneOfficer | Sale at price 86.03 per share. | 146 | $12.59K |
| Jul 27, 2026 | Markowitz WayneOfficer | Sale at price 85.06 per share. | 9.6K | $818.96K |
| Jul 27, 2026 | Markowitz WayneOfficer | Conversion of Exercise of derivative security at price 74.02 per share. | 9.6K | $712.66K |
| Jul 26, 2026 | Zovighian Bernard JChief Executive Officer | Sale at price 83.93 per share. | 2.9K | $245.13K |
| Jul 26, 2026 | Zovighian Bernard JChief Executive Officer | Stock Gift at price 0.00 per share. | 319 | — |
| Jul 9, 2026 | Lippis Daniel JOfficer | Sale at price 91.70 per share. | 619 | $56.76K |
| Jul 9, 2026 | Lippis Daniel JOfficer | Conversion of Exercise of derivative security at price 72.68 per share. | 619 | $44.99K |
| Jul 8, 2026 | Mistras TheodoraChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 99.9K | — |
| Jun 29, 2026 | Lippis Daniel JOfficer | Sale at price 91.40 per share. | 619 | $56.58K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -4.6 | 6.3 | -7.4 | 4.3 | 3.6 | 4.6 | -4.9 | 5.4 | -4.9 | 0.1 | +1.3% | ||
| 2025 | -2.1 | -1.1 | 1.2 | 4.2 | 3.6 | -0.0 | 1.4 | 2.6 | -4.4 | 6.0 | 5.1 | -1.6 | +15.2% |
| 2024 | 2.9 | 8.2 | 12.6 | -11.4 | 2.6 | 6.3 | -31.7 | 11.0 | -5.7 | 1.5 | 6.5 | 3.8 | −2.9% |
| 2023 | 2.8 | 4.9 | 2.8 | 6.3 | -4.3 | 12.0 | -13.0 | -6.8 | -9.4 | -8.0 | 6.3 | 12.6 | +2.2% |
| 2022 | -15.7 | 2.9 | 4.8 | -10.1 | -4.7 | -5.7 | 5.7 | -10.4 | -8.3 | -12.3 | 6.7 | -3.4 | −42.4% |
| 2021 | -9.5 | 0.6 | 0.6 | 14.2 | 0.4 | 8.0 | 8.4 | 4.4 | -3.4 | 5.8 | -10.4 | 20.7 | +42.0% |
| 2020 | -5.8 | -6.8 | -7.9 | 15.3 | 3.3 | -7.7 | 13.5 | 9.5 | -7.0 | -10.2 | 17.0 | 8.7 | +17.3% |
| 2019 | 11.3 | -0.7 | 13.0 | -8.0 | -3.0 | 8.2 | 15.2 | 4.2 | -0.9 | 8.4 | 2.8 | -4.8 | +52.3% |
| 2018 | 12.3 | 5.6 | 4.4 | -8.7 | 7.8 | 6.0 | -2.1 | 1.3 | 20.7 | -15.2 | 9.8 | -5.5 | +35.9% |
| 2017 | 2.7 | -2.3 | 0.0 | 16.6 | 4.9 | 2.8 | -2.6 | -1.3 | -3.8 | -6.5 | 14.6 | -3.8 | +20.3% |
| 2016 | -1.0 | 11.2 | 1.4 | 20.4 | -7.3 | 1.2 | 14.8 | 0.6 | 4.7 | -21.0 | -13.0 | 13.1 | +18.6% |
| 2015 | -1.6 | 6.1 | 7.1 | -11.1 | 3.2 | 9.0 | 6.8 | -7.4 | 0.9 | 10.5 | 3.7 | -3.1 | +24.0% |
| 2014 | -1.0 | 7.1 | 6.3 | 9.8 | -0.3 | 5.7 | 5.1 | 10.0 | 2.9 | 18.4 | 7.2 | -1.8 | +93.7% |
| 2013 | -0.3 | -4.4 | -4.4 | -22.4 | 4.2 | 1.1 | 6.2 | -1.4 | -1.1 | -6.4 | 0.5 | 0.4 | −27.1% |
| 2012 | 16.9 | -11.5 | -0.5 | 14.1 | 2.9 | 21.0 | -2.0 | 0.9 | 5.2 | -19.1 | -0.1 | 3.9 | +27.5% |
| 2011 | 4.3 | 0.9 | 2.3 | -0.7 | 2.8 | -1.7 | -18.2 | 5.7 | -5.5 | 5.8 | -12.5 | 7.1 | −12.5% |
| 2010 | 3.2 | 2.5 | 7.7 | 4.2 | -2.0 | 10.9 | 3.2 | -0.4 | 16.5 | -4.7 | 3.8 | 21.8 | +86.2% |
| 2009 | 4.6 | -3.3 | 9.0 | 4.5 | 0.7 | 6.6 | -3.9 | -5.4 | 13.0 | 10.1 | 6.9 | 5.6 | +58.1% |
| 2008 | 0.6 | -5.7 | 2.2 | 24.4 | 4.1 | 7.5 | 1.0 | -5.5 | -2.4 | -8.5 | -5.8 | 10.4 | +19.5% |
| 2007 | 8.8 | -1.5 | 0.6 | -3.4 | 2.4 | -1.7 | -6.9 | 5.1 | 2.1 | 1.8 | -1.5 | -7.0 | −2.2% |
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Buy / hold / sell counts